The Effects of Rosiglitazione on Renal Artery Endothelium in Diabetic Rats

Abstract

Backround: Macrovascular disease is a common complication of Diabetes Mellitus (DM). Study of renal artery endothelium may serve as a surrogate for cardiovascular and renal vascular disease.

Object: This study is to elucidate (1) how about the changes of renal endothelial ultrastructures it is in different time of diabetes animals? (2) Whether PPARgamma ligand (such as rosiglitazone: ROS) could improve endothelium destruction in diabetes?

Methods: Streptozoticin (STZ) induced diabetic rats were stratified by age groups from 6 to 10 weeks of age and were paired with age-matched control non-diabetic rats. Further, another group of diabetic rats were treated with ROS and matched with non-treated diabetic rats.

Result: The renal artery endothelium of diabetic rats was partially coarse, distended, cracked and destroyed. The Vascular Endothelial Structure Score (VESS) was 34.5 in diabetic rats compared with non-diabetic control male rats (P=0.001). The older rats demonstrated more endothelial wall damage, more pronounced in male rats. Compared with non-treated control diabetic rats, ROS prevented diabetic endothelial damage (VESS=4.6, P=0.001).

Conclusion: Renal artery endothelium damage in STZ induced diabetic rats was significantly attenuated by rosiglitazone.

Key words

diabetes - renal artery - endothelial - rosiglitazione

References

• 1 Sowers JR, Frohlich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease.  Med Clin North Am. 2004;  88 63-82
• 2 Lashin O, Romani A. Mitochondria respiration and susceptibility to ischemia-reperfusion injury in diabetic hearts.  Arch Biochem Biophys. 2003;  420 298-304 , . DOI: 10.1016/j.abb.2003.09.024
• 3 Furuta M, Tsunoda K, Arita M. et al . Endothelium-dependent vasodilation in type α diabetes mellitus.  Rinsho Byori. 2003;  51 1111-1115
• 4 Granstam E, Granstam SO. Involvement of nitric oxide in the regulation of regional hemodynamics in streptozotocin-diabetic rats.  Physiol Res. 2003;  52 159-169
• 5 Dandona P, Aljada A, Chaudhuri A. Vascular reactivity and thiazolidinediones.  Am J Med. 2003;  8 115 , (Suppl 8A): 81S–86S. DOI: 10.1016/j.amjmed.2003.08.015
• 6 Freedman BI, Hsu FC, Langefeld CD. et al . Renal artery calcified plaque associations with subclinical renal and cardiovascular disease.  Kidney Int. 2004;  65 2262-2267 , . DOI: 10.1111/j.1523-1755.2004.00645.x
• 7 Shestakova MV, Iarek-Martynov IR, Ivanishina NS. et al . Assessment of vasomotor endothelial function in patients with diabetes mellitus type 1 at different stages of diabetic nephropathy.  Ter Arkh. 2003;  75 17-21
• 8 Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management.  Am J Hypertens. 1999;  12 ((12 Pt 3)) 205-213 , . DOI: 10.1016/S0895-7061(99)00103-X
• 9 Lods N, Ferrari P, Frey FJ. et al . Angiotensin-converting enzyme inhibition but not angiotensin α receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis.  J Am Soc Nephrol. 2003;  14 2861-2872 , . DOI: 10.1097/01.ASN.0000092789. 67966.5C
• 10 Masami N, Rimei N, Takashi S. et al . Genetic association of glutathione peroxidase-1 with coronary artery calcification in type 2 diabetes: a case control study with multi-slice computed tomography.  Cardiovascular Diabetology. 2007;  6 23. , DOI:10.1186/1475-2840-6-23
• 11 Charles WB, Payne MA, Macdonald WG. et al . Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat.  Diabetes and Vascular Disease Research. 2007;  4 117-123
• 12 Rhee EJ, Kwon CH, Lee WY. et al . No Association of Pro12Ala polymorphism of PPAR gene with coronary artery disease in Korean subjects.  Circ J. 2007;  71 338-342
• 13 Hong SJ, Seo HS, Rha SW. et al . Decrease in plasma adiponectin concentrations in patients with variant angina pectoris.  Circ J. 2006;  70 414-418
• 14 Lin Y, Zhu X, MacLntee FL. et al . Interferon regulatory factor-1 mediates PPARgamma-induced apoptosis in vascular smooth muscle cells.  Arterioscler Thromb Vasc Biol. 2004;  24 257-263 , . DOI: 10.1161/01.ATV.0000109170.43400.2f
• 15 Brodsky SV, Gealekman O, Chen J. et al . Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen.  Circ Res. 2004;  94 ((3)) 377-384 , . DOI: 10.1161/01.RES.0000111802.09964.EF
• 16 Shen B, Ye CL, Ye KH. et al . Mechanism underlying enhanced endothelium-dependent vasodilatation in thoracic aorta of early stage streptozotocin-induced diabetic mice.  Acta Pharmacol Sin. 2003;  24 422-428
• 17 Di Loreto S, Caracciolo V, Colafarina S. et al . Methylglyoxal induces oxidative stress-dependent cell injury and up-regulation of interleukin-1beta and nerve growth factor in cultured hippocampal neuronal cells.  Brain Res. 2004;  1006 157-167 , . DOI: 10.1016/j.brainres.2004. 01.066
• 18 Schwartz IF, Iaina A, Benedict Y. et al . Augmented arginine uptake, through modulation of cationic amino acid transporter-1, increases GFR in diabetic rats.  Kidney Int. 2004;  65 1311-1319 , . DOI: 10.1111/j.1523-1755.2004.00508.x
• 19 Tonelli J, Li W, Kishore P. et al . Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.  Diabetes. 2004;  53 1621-1629
• 20 Campbell IW. Long-term glycaemic control with pioglitazone in patients with type 2 diabetes.  Int J Clin Pract. 2004;  58 192-200
• 21 Del Prato S, Volpe L. Rosiglitazone plus metformin: combination therapy for type 2 diabetes.  Expert Opin Pharmacother. 2004;  5 1411-1422 , . DOI: 10.1517/14656566.5.6.1411
• 22 Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus.  Am J Med. 2003;  , 8;115 ((Suppl 8A)) 42-48 , . DOI: 10.1016/j.amjmed.2003.09.005
• 23 Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones.  Am J Med. 2003;  , 8;115 ((Suppl 8A)) 111-115 , . DOI: 10.1016/j.amjmed.2003.09.018
• 24 Reusch JE, Regensteiner JG, Watson PA. Novel actions of thiazolidinediones on vascular function and exercise capacity.  Am J Med. 2003;  , 8;115 ((Suppl 8A)) 69-74 , . DOI: 10.1016/j.amjmed.2003.09.012
• 25 Koc M, Bihorac A, Segal MS. Circulating endothelial cells as potential markers of the state of the endothelium in hemodialysis patients.  Am J Kidney Dis. 2003;  42 704-712
• 26 Lu YL, Hu SJ, Shen ZJ. et al . Changes of macrovascular endothelial ultrastructure and gene expression of endothelial nitric oxide synthase in diabetic rats.  Chin Med J (Engl). 2004;  117 1165-1169
• 27 Murakami H, Shimamoto K. How to prevent the incidence of hypertension in type 2 diabetes patients.  Nippon Rinsho. 2003;  61 1154-1156
• 28 Affonso Fde S, Cailleaux S, Pinto LF. et al . Effects of high glucose concentrations on the endothelial function of the renal microcirculation of rabbits.  Arq Bras Cardiol. 2003;  81 161-165 , , 156–60.
• 29 MacGinn S, Poronnik P, King M. et al . High glucose and endothelial cell growth: novel effects independent of autocrine TGF-beta 1 and hyperosmolarity.  Am J Physiol Cell Physiol. 2003;  284 C1374-C1386 , . DOI: 10.1152/ajpcell.00466.2002

Correspondence